Literature DB >> 7586544

Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid.

W M Zhang1, J Leinonen, N Kalkkinen, B Dowell, U H Stenman.   

Abstract

We have developed a new procedure for purifying prostate-specific antigen (PSA) from human seminal fluid. The method is based on ammonium sulfate precipitation, hydrophobic interaction chromatography, gel filtration, and anion-exchange chromatography. It can be completed within 2 days with a recovery of intact PSA of 30%. By anion-exchange chromatography, five isoforms of PSA (A, B, C, D, and E) can be separated. The major form (PSA-B) consists of the intact enzyme, as shown by the occurrence of only one band of 33 kDa in sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing or nonreducing conditions, and by amino acid sequencing, which reveals only one amino-terminal sequence corresponding to the reported amino-terminal sequence of intact PSA. The specific absorbance of 1 g/L PSA-B at 280 nm was 1.61, and 80% of the PSA-B formed a complex with alpha 1-antichymotrypsin, indicating that it is enzymatically active. Three cleaved forms of PSA with different nicking sites and low enzymatic activity were separated from intact PSA by ion-exchange chromatography. In addition, we isolated a glycosylation variant, PSA-A, which showed a higher isoelectric point (pI = 7.2) than PSA-B (pI = 6.9) but similar enzymatic activity; this form accounts for 5-10% of total PSA. After treatment with sialidase, PSA-A and B had the same isoelectric point value (pI = 7.7).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586544

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  23 in total

1.  Expression and characterization of trypsinogen produced in the human male genital tract.

Authors:  A Paju; A Bjartell; W M Zhang; S Nordling; A Borgström; J Hansson; U H Stenman
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

2.  Twenty Years of PSA: From Prostate Antigen to Tumor Marker.

Authors:  Gabriela De Angelis; Harry G Rittenhouse; Stephen D Mikolajczyk; L Blair Shamel; Axel Semjonow
Journal:  Rev Urol       Date:  2007

3.  Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples.

Authors:  Akos Végvári; Melinda Rezeli; Jari Häkkinen; Carina Sihlbom; Elisabet Carlsohn; Johan Malm; Hans Lilja; Thomas Laurell; György Marko-Varga
Journal:  J Proteomics       Date:  2011-06-23       Impact factor: 4.044

4.  Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry.

Authors:  Ákos Végvári; Melinda Rezeli; Carina Sihlbom; Jari Häkkinen; Elisabet Carlsohn; Johan Malm; Hans Lilja; Thomas Laurell; György Marko-Varga
Journal:  Clin Biochem       Date:  2011-12-16       Impact factor: 3.281

5.  Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.

Authors:  Shahrokh F Shariat; Eduardo I Canto; Michael W Kattan; Kevin M Slawin
Journal:  Rev Urol       Date:  2004

6.  Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆).

Authors:  Mari T Peltola; Pauliina Niemelä; Kalle Alanen; Martti Nurmi; Hans Lilja; Kim Pettersson
Journal:  J Immunol Methods       Date:  2011-04-28       Impact factor: 2.303

7.  Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour.

Authors:  Elteza Tahjiba Jahir; Runi Devi; Bibhuti Bhushan Borthakur
Journal:  J Clin Diagn Res       Date:  2017-03-01

Review 8.  Aberrant PSA glycosylation--a sweet predictor of prostate cancer.

Authors:  Sarah Gilgunn; Paul J Conroy; Radka Saldova; Pauline M Rudd; Richard J O'Kennedy
Journal:  Nat Rev Urol       Date:  2013-01-15       Impact factor: 14.432

9.  Evaluation of molecular species of prostate-specific antigen complexed with immunoglobulin M in prostate cancer and benign prostatic hyperplasia.

Authors:  Sanja Goč; Miroslava Janković
Journal:  Dis Markers       Date:  2013-12-03       Impact factor: 3.434

10.  Potential clinical importance of the activation peptide of prostate-specific antigen.

Authors:  Laura M Voeghtly; Ida B Thøgersen; Zuzana Valnickova; Kristian W Sanggaard; Charleen T Chu; Tim D Oury; Jan J Enghild
Journal:  Int J Clin Exp Pathol       Date:  2009-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.